Hypofractionated Stereotactic Radiation Therapy to the Resection Bed for Intracranial Metastases
- PMID: 28974415
- DOI: 10.1016/j.ijrobp.2017.08.014
Hypofractionated Stereotactic Radiation Therapy to the Resection Bed for Intracranial Metastases
Abstract
Purpose: To retrospectively report the outcomes of a large multicenter cohort of patients treated with surgery and hypofractionated stereotactic radiation therapy (HFSRT) to the resection cavities of brain metastases (BMs).
Methods and materials: Between March 2008 and February 2015, 181 patients with no prior whole-brain radiation therapy (WBRT) were treated by HFSRT to the surgical bed of BM at the dose of 33 Gy (3 × 11 Gy). The primary endpoint was local control. Secondary endpoints were distant brain control, overall survival (OS), risk of radionecrosis, and leptomeningeal disease (LMD).
Results: Of the 189 resected lesions, 44% were metastatic from a non-small cell lung cancer primary tumor, and 76% of patients had a single BM at the time of treatment. With a median follow-up of 15 months, the 6- and 12-month local control rates were 93% and 88%, respectively. On multivariate analysis, planning target volume (P=.005), graded prognostic assessment score (P=.021), and meningeal contact of BM (P=.032) were predictive of local failure. The 6- and 12-month distant brain control rates were 70% and 61%, respectively. Twenty-six patients (14%) developed signs of LMD at a median time of 3.8 months. The preoperative tumor volume was predictive of LMD (P=.029). The median OS was 17 months. The 6-, 12-, and 24-month OS rates were 79%, 62%, and 39%, respectively. Recursive partitioning analysis class 3 (P=.02), piecemeal resection (P=.017), and an increasing number of BMs (P<.01) were independent unfavorable prognostic factors for OS. Fifty-four patients (30%) were subsequently treated with salvage WBRT at a median time of 6.5 months, and 41% were reirradiated with SRT. Radionecrosis occurred in 19% of cases at a median time of 15 months and was associated with the infratentorial location of the BM (P=.0025).
Conclusions: This study demonstrated the safety and efficacy of a 3 × 11 Gy HFSRT regimen for the irradiation of BMs resection cavities. It was an alternative to adjuvant WBRT.
Copyright © 2017. Published by Elsevier Inc.
Similar articles
-
Stereotactic radiosurgery to the resection bed for intracranial metastases and risk of leptomeningeal carcinomatosis.J Neurosurg. 2014 Dec;121 Suppl:75-83. doi: 10.3171/2014.6.GKS14708. J Neurosurg. 2014. PMID: 25434940
-
Prognostic factors for survival in patients treated with stereotactic radiosurgery for recurrent brain metastases after prior whole brain radiotherapy.Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):303-9. doi: 10.1016/j.ijrobp.2011.06.1987. Epub 2011 Nov 11. Int J Radiat Oncol Biol Phys. 2012. PMID: 22079723
-
Risk of leptomeningeal disease in patients treated with stereotactic radiosurgery targeting the postoperative resection cavity for brain metastases.Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):713-8. doi: 10.1016/j.ijrobp.2013.07.034. Epub 2013 Sep 18. Int J Radiat Oncol Biol Phys. 2013. PMID: 24054875
-
Stereotactic Radiosurgery for Postoperative Metastatic Surgical Cavities: A Critical Review and International Stereotactic Radiosurgery Society (ISRS) Practice Guidelines.Int J Radiat Oncol Biol Phys. 2021 Sep 1;111(1):68-80. doi: 10.1016/j.ijrobp.2021.04.016. Epub 2021 Apr 20. Int J Radiat Oncol Biol Phys. 2021. PMID: 33891979 Review.
-
Single- and Multifraction Stereotactic Radiosurgery Dose/Volume Tolerances of the Brain.Int J Radiat Oncol Biol Phys. 2021 May 1;110(1):68-86. doi: 10.1016/j.ijrobp.2020.08.013. Epub 2020 Sep 11. Int J Radiat Oncol Biol Phys. 2021. PMID: 32921513 Free PMC article. Review.
Cited by
-
Intraoperative radiotherapy after neurosurgical resection of brain metastases as institutional standard treatment- update of the oncological outcome form a single center cohort after 117 procedures.J Neurooncol. 2024 Aug;169(1):187-193. doi: 10.1007/s11060-024-04691-6. Epub 2024 Jul 4. J Neurooncol. 2024. PMID: 38963657 Free PMC article.
-
CSCO expert consensus on the diagnosis and treatment of breast cancer brain metastasis.Transl Breast Cancer Res. 2022 Jul 30;3:22. doi: 10.21037/tbcr-22-30. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751521 Free PMC article. Review.
-
Novel radiotherapeutic strategies in the management of brain metastases: Challenging the dogma.Neuro Oncol. 2024 Mar 4;26(12 Suppl 2):S46-S55. doi: 10.1093/neuonc/noad260. Neuro Oncol. 2024. PMID: 38437668 Review.
-
Modern Stereotactic Radiotherapy for Brain Metastases from Lung Cancer: Current Trends and Future Perspectives Based on Integrated Translational Approaches.Cancers (Basel). 2023 Sep 18;15(18):4622. doi: 10.3390/cancers15184622. Cancers (Basel). 2023. PMID: 37760591 Free PMC article. Review.
-
Opportunities and Alternatives of Modern Radiation Oncology and Surgery for the Management of Resectable Brain Metastases.Cancers (Basel). 2023 Jul 19;15(14):3670. doi: 10.3390/cancers15143670. Cancers (Basel). 2023. PMID: 37509330 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical